伏立康唑缓释基质制剂的制备与评价

Shereen Abd El Gawad, M. Marzouk, A. Ammar
{"title":"伏立康唑缓释基质制剂的制备与评价","authors":"Shereen Abd El Gawad, M. Marzouk, A. Ammar","doi":"10.21608/ajps.2023.311244","DOIUrl":null,"url":null,"abstract":"Voriconazole is a triazole antifungal with a half-life of 1.7 hours and 96% oral bioavailability. The oral route is the most popular of drug delivery routes. However, there are a few limitations to the traditional dosage form, for instance, fluctuations in plasma drug level. Sustained drug delivery system overcomes these limitations; it helps to maintain stable plasma drug concentrations by decreasing drug r elease and extending the duration of the effect. The main purpose of this study was to formulate voriconazole sustained release dosage form to enhance efficacy, decrease dose frequency, decrease its side effects, and improve patient compliance. The study explored various formulations for producing the sustained-release (S.R) dosage form, as well as assessed the drug's release kinetics and its stability. Methodology : Fourier-transform Infrared Spectroscopy was used to investigate drug-polymer compatibility. The micromeritics of voriconazole powder and its blends were evaluated. Different sustained release tablets were formulated utilizing a wet granulation process and acrylic polymers (Eudragit) i.e., Eudragit RL100 and RS100 alone and as mixtures with different ratios, in different concentrations. In-vitro drug release of formulae was performed for 24 hours. The formula with desired control of drug release and complied with dissolution specifications for SR dosage forms was further evaluated for its stability by storage for 3 months at 30 o C and 40 o C and 75% relative humidity. Results : no interaction was observed between voriconazole and polymers using FTIR. The powder blends micromeritics were found to be in accordance with the specification. Tablets showed release from 37.29 to 76 % up to 24 hr using USP type I technique. It was found that as polymer concentration increased, the drug release from tablet decreased. The selected formulation F13 which containing 5% of Eudragit RL100:RS100 at a ratio of (10:1) was found to be stable. Conclusion : The obtained data concluded that the F13 formula gave more prominent S.R effect than using Eudragit RL100 or RS 100 alone.","PeriodicalId":7603,"journal":{"name":"Al-Azhar Journal of Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PREPARATION AND EVALUATION OF SUSTAINED RELEASE MATRIX FORMULATIONS OF VORICONAZOLE\",\"authors\":\"Shereen Abd El Gawad, M. Marzouk, A. Ammar\",\"doi\":\"10.21608/ajps.2023.311244\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Voriconazole is a triazole antifungal with a half-life of 1.7 hours and 96% oral bioavailability. The oral route is the most popular of drug delivery routes. However, there are a few limitations to the traditional dosage form, for instance, fluctuations in plasma drug level. Sustained drug delivery system overcomes these limitations; it helps to maintain stable plasma drug concentrations by decreasing drug r elease and extending the duration of the effect. The main purpose of this study was to formulate voriconazole sustained release dosage form to enhance efficacy, decrease dose frequency, decrease its side effects, and improve patient compliance. The study explored various formulations for producing the sustained-release (S.R) dosage form, as well as assessed the drug's release kinetics and its stability. Methodology : Fourier-transform Infrared Spectroscopy was used to investigate drug-polymer compatibility. The micromeritics of voriconazole powder and its blends were evaluated. Different sustained release tablets were formulated utilizing a wet granulation process and acrylic polymers (Eudragit) i.e., Eudragit RL100 and RS100 alone and as mixtures with different ratios, in different concentrations. In-vitro drug release of formulae was performed for 24 hours. The formula with desired control of drug release and complied with dissolution specifications for SR dosage forms was further evaluated for its stability by storage for 3 months at 30 o C and 40 o C and 75% relative humidity. Results : no interaction was observed between voriconazole and polymers using FTIR. The powder blends micromeritics were found to be in accordance with the specification. Tablets showed release from 37.29 to 76 % up to 24 hr using USP type I technique. It was found that as polymer concentration increased, the drug release from tablet decreased. The selected formulation F13 which containing 5% of Eudragit RL100:RS100 at a ratio of (10:1) was found to be stable. Conclusion : The obtained data concluded that the F13 formula gave more prominent S.R effect than using Eudragit RL100 or RS 100 alone.\",\"PeriodicalId\":7603,\"journal\":{\"name\":\"Al-Azhar Journal of Pharmaceutical Sciences\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Al-Azhar Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/ajps.2023.311244\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Al-Azhar Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/ajps.2023.311244","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

伏立康唑是一种三唑类抗真菌药物,半衰期为1.7小时,口服生物利用度为96%。口服给药途径是最常用的给药途径。然而,传统的剂型存在一些局限性,例如,血浆药物水平的波动。持续给药系统克服了这些限制;它通过减少药物释放和延长作用时间来帮助维持稳定的血浆药物浓度。本研究的主要目的是制定伏立康唑缓释剂型,以提高疗效,减少给药频率,减少副作用,提高患者依从性。本研究探索了生产缓释剂型的各种配方,并评估了药物的释放动力学和稳定性。方法:采用傅里叶变换红外光谱法研究药物-聚合物的相容性。对伏立康唑粉末及其共混物进行了显微测量。不同的缓释片采用湿造粒工艺和丙烯酸聚合物(Eudragit),即Eudragit RL100和RS100单独以及不同比例,不同浓度的混合物配制。体外释放时间为24小时。通过在30℃、40℃、75%相对湿度条件下贮存3个月,进一步评价该制剂的稳定性。结果:伏立康唑与聚合物在FTIR中未见相互作用。粉末共混物的显微指标符合规定。使用USP I型技术,片剂在24小时内释放率为37.29% ~ 76%。结果表明,随着聚合物浓度的增加,药物释放量减小。所选择的配方F13,含5%乌龙茶RL100:RS100,比例为(10:1),稳定性较好。结论:所得数据表明,F13配方比乌龙茶RL100或单独使用乌龙茶RL100具有更显著的S.R效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
PREPARATION AND EVALUATION OF SUSTAINED RELEASE MATRIX FORMULATIONS OF VORICONAZOLE
Voriconazole is a triazole antifungal with a half-life of 1.7 hours and 96% oral bioavailability. The oral route is the most popular of drug delivery routes. However, there are a few limitations to the traditional dosage form, for instance, fluctuations in plasma drug level. Sustained drug delivery system overcomes these limitations; it helps to maintain stable plasma drug concentrations by decreasing drug r elease and extending the duration of the effect. The main purpose of this study was to formulate voriconazole sustained release dosage form to enhance efficacy, decrease dose frequency, decrease its side effects, and improve patient compliance. The study explored various formulations for producing the sustained-release (S.R) dosage form, as well as assessed the drug's release kinetics and its stability. Methodology : Fourier-transform Infrared Spectroscopy was used to investigate drug-polymer compatibility. The micromeritics of voriconazole powder and its blends were evaluated. Different sustained release tablets were formulated utilizing a wet granulation process and acrylic polymers (Eudragit) i.e., Eudragit RL100 and RS100 alone and as mixtures with different ratios, in different concentrations. In-vitro drug release of formulae was performed for 24 hours. The formula with desired control of drug release and complied with dissolution specifications for SR dosage forms was further evaluated for its stability by storage for 3 months at 30 o C and 40 o C and 75% relative humidity. Results : no interaction was observed between voriconazole and polymers using FTIR. The powder blends micromeritics were found to be in accordance with the specification. Tablets showed release from 37.29 to 76 % up to 24 hr using USP type I technique. It was found that as polymer concentration increased, the drug release from tablet decreased. The selected formulation F13 which containing 5% of Eudragit RL100:RS100 at a ratio of (10:1) was found to be stable. Conclusion : The obtained data concluded that the F13 formula gave more prominent S.R effect than using Eudragit RL100 or RS 100 alone.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信